A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia

Trial Profile

A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Peripheral ischaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors AnGes MG
  • Most Recent Events

    • 26 Mar 2017 This trial has been completed in Hungary (end date: 6 Mar 2017).
    • 23 Mar 2017 This trial has been completed in Spain (end date: 6 Mar 2017).
    • 21 Jun 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top